Results 231 to 240 of about 12,854,723 (342)

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin   +2 more
wiley   +1 more source

Proportion of Acceptable Symptom State Nearly Tripled With Improvements in Patient‐Reported Outcomes for All Symptom State Subgroups: A Registry Study of More Than 15,000 Patients With Osteoarthritis in Digital Education and Exercise Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective This study investigated trajectories of patient acceptable symptom state (PASS) among participants of digital education and exercise therapy for knee and hip osteoarthritis. Methods A longitudinal observational study among individuals aged at least 40 years who participated in the digital program.
Ali Kiadaliri   +3 more
wiley   +1 more source

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus. [PDF]

open access: yesNutr Diabetes, 2021
Wolf VLW   +13 more
europepmc   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy